Hoersholm, 2014-04-09 08:00 CEST (GLOBE NEWSWIRE) --
Company announcement no. 15/2014
“Following a strong Q2 with 10% organic growth and solid margin development we remain on track to deliver on our outlook for the full year, expecting organic revenue growth of 7-9% and an EBIT margin before special items above 26%. We have continued to implement our Nature’s No. 1 strategy with initiatives to support the future growth and profitability of Chr. Hansen. I am especially pleased with the good performance of both the Cultures & Enzymes Division and the EMEA region in general as well as to see the first sales of cultures for crop protection,” says CEO Cees de Jong.
Highlights YTD 2013/14
OUTLOOK FOR 2013/14
The outlook for 2013/14 is unchanged from the announcement of 15 January 2014.
Organic revenue growth:7‐9%
Research & development expenditures incurred (% of revenue): toward 7%
Negative impact on EBIT margin from increased research & development activity and lower level of capitalization: 1-1.5%-point
EBIT margin before special items:above 26%
Special items (cost): EUR 8-10 million
Free cash flow before acquisitions and divestments: around EUR 110 million
This report contains forward-looking statements. Such statements are subject to risks and uncertainties, as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in this report.
The report has been prepared in English and Danish. The Danish text shall govern for all purposes and prevail in the event of any discrepancy between the versions.
About Chr. Hansen
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. Products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2012/13 financial year was EUR 738 million. The Company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in 30 countries and main production facilities in Denmark, France, the US and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen. For further information, please visit www.chr-hansen.com.